PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

ADA Standards of Care: Pharmacologic Treatment of Obesity in Adults

The ADA's new Obesity Association guideline reframes obesity pharmacotherapy around treating obesity-related diseases rather than weight targets alone, elevates GLP-1RA and dual GIP/GLP-1RA agents to preferred status across multiple comorbidities, and mandates indefinite continuation to prevent weight recurrence.
ADA Standards of Care in Overweight and Obesity 2025The Obesity Association (American Diabetes Association)obesity/overweightGLP-1 receptor agonistsdual GIP/GLP-1 receptor agonistsphentermine-topiramatenaltrexone-bupropionorlistat Obesity / Weight Management
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: American Diabetes Association Professional Practice Committee for Obesity

Citation: American Diabetes Association Professional Practice Committee for Obesity Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. BMJ open diabetes research & care. 2026;13(Suppl 1). doi:10.1136/bmjdrc-2025-005729

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →